GlassScriptPhysician profile
Sarvarinder Gill
NPI 1023647070
$1,084.46
in general payments reported to CMS, 2019-2025
15 companies · $788 in 2025
The $788 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $297 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.47 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $286.60 | 2025 | Jakafi, Jakafi |
| Sobi, INC | $169.41 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.57 | 2024-2025 | Iclusig |
| Alexion Pharmaceuticals, INC. | $99.99 | 2025 | Soliris |
| Genzyme Corporation | $86.68 | 2024-2025 | |
| Blueprint Medicines Corporation | $69.11 | 2024-2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $63.88 | 2024 | Keytruda, Lynparza |
| Taiho Oncology, INC. | $34.87 | 2025 | |
| Geron Corporation | $30.82 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $20.32 | 2024 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2025 | |
| Glaxosmithkline, LLC. | $18.41 | 2025 | Ojjaara |
| Lilly USA, LLC | $18.37 | 2024 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $17.00 | 2025 | Tecvayli |
| Blue Earth Diagnostics | $15.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarvarinder Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.